Wednesday, June 15, 2011
Drug combination extends survival in refractory lung cancer patients
Drug combination extends survival in refractory lung cancer patients
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1. The drug combination also broadened the reach to include a specific subset of patients, such as those
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment